

British Journal of Pharmacology

Proceedings Supplement

Proceedings of the British Pharmacological Society Meeting

11 – 12 April 2002

**University of Hertfordshire
(Hatfield Campus)**

The *British Journal of Pharmacology* is published by Nature Publishing Group, a division of Macmillan Publishers Ltd. It is the official publication of the British Pharmacological Society.

Scope The *British Journal of Pharmacology* publishes 3 volumes of 8 issues per year and is published twice a month. It welcomes contributions in all fields of experimental pharmacology including neuroscience, biochemical, cellular and molecular pharmacology. The Board of Editors represents a wide range of expertise and ensures that well-presented work is published as promptly as possible, consistent with maintaining the overall quality of the journal.

This journal is covered by Current Contents, EMBASE/Excerpta Medica, BIOSIS, Elsevier Biobase/Current Awareness in Biological Sciences, CINAHL and Index Medicus.

Editorial Manuscripts should be submitted online at <http://www.brjpharmacol.org>; authors unable to submit online should send one copy of their manuscript, plus a copy on disk, together with a covering letter to: The Editorial Office, British Journal of Pharmacology, BPS Office, 16 Angel Gate, 326 City Road, London EC1V 2SG, UK. Tel: +44 20 7417 0432. Fax: +44 20 7417 0430; aam@bps.ac.uk.

Publisher All business correspondence and enquiries about supplement publication and sponsorship opportunities should be addressed to *British Journal of Pharmacology*, Nature Publishing Group, Houndmills, Basingstoke, Hampshire RG21 6XS, UK. Tel: +44 1256 329242; Fax: +44 1256 810526. Publishing Manager: Jason Wilde. Production Controller: Jane Torr.

The *British Journal of Pharmacology* is online at: www.brjpharmacol.org. Visit the journal's home pages for details of the aims and scope, readership, instructions to authors and how to contact the Editors and publishing staff. Use the website to order a subscription, reprints or a sample copy.

Free to all readers: tables of contents for all articles published since 1965, abstracts for all articles since 1975 and the complete text of the January 2001 issue. Register to receive the table of contents by e-mail as each issue is published.

Subscribers to the 2002 online version of the journal have access to PDF files of all articles since 1997. The full text of all articles in HTML format is also available from 2002.

Subscriptions – 2002 subscription rates

INSTITUTIONAL SUBSCRIPTIONS

Combined (electronic online & print): EU £1238, Rest of World £1238/US\$1857

Electronic online only: £1125/US\$1688

Print (hard copy) only: EU £1125; Rest of World £1125/US\$1688

Prices for airmail delivery on application.

Site licences and institutional online access – for information on multi-user or multi-site access to Nature Publishing Group products please contact s.archer@macmillan.co.uk or telephone +44 20 7843 6426. For other enquiries please contact sjsupport@nature.com or telephone +44 20 7843 4759.

PERSONAL SUBSCRIPTIONS (USA only)

Combined (electronic & print): US\$352

Electronic online only: US\$320

Print (hard copy) only: US\$320

Subscriptions – Outside the USA

Orders must be accompanied by remittance. Cheques should be made payable to Nature Publishing Group and sent to: The Subscription Department, Nature Publishing Group, Houndmills, Basingstoke, Hampshire RG21 6XS, UK. E-mail: subscriptions@nature.com. Where appropriate, subscribers may make payments into UK Post Office Giro Account No: 519 2455. Full details must accompany the payment.

Subscriptions – USA

USA subscribers can call toll free: 1 800 747 3187. Please send check/money order/credit card details to: The Subscription Department, Nature Publishing Group, Houndmills, Basingstoke, Hampshire RG21 6XS, UK. E-mail: subscriptions@nature.com.

Prices are set in UK Sterling. Dollar prices are converted from UK Sterling at the current exchange rate. Accordingly, your credit card charge may vary slightly from the Dollar rate shown. To obtain the exact Dollar rate shown, please remit by check. All prices, specifications and details are subject to change without prior notification.

British Journal of Pharmacology (ISSN 0007–1188) is published twice a month by Nature Publishing Group, c/o Mercury Airfreight International Ltd, 365 Blair Road, Avenel, NJ 07001, USA. Subscription price for institutions is \$1688 per annum. Periodicals postage is paid at Rahway NJ. Postmaster: send address corrections to *British Journal of Pharmacology*, Nature Publishing Group, c/o Mercury Airfreight International Ltd, 365 Blair Road, Avenel, NJ 07001.

Advertisements Enquiries concerning advertisements should be addressed to: Robert Sloan, Advertisement Manager, 84 Arncliffe Grove, Southgate, London N14 7AR, UK. Tel: +44 20 8882 7199; Fax: +44 20 8882 7299; E-mail: rsloan@rsa2.demon.co.uk

Reprints and permissions For reprints of any article in this journal or reproduction rights, please contact Tracé Noel (t.noel@nature.com) at the Publisher's address (above).

Copyright © 2002 Nature Publishing Group

ISSN 0007–1188

All rights of reproduction are reserved in respect of all papers, articles, illustrations, etc., published in this journal in all countries of the world.

All material published in this journal is protected by copyright, which covers exclusive rights to reproduce and distribute the material. No material published in this journal may be reproduced or stored on microfilm or in electronic, optical or magnetic form without the written authorisation of the Publisher.

Authorisation to photocopy items for internal or personal use of specific clients, is granted by Nature Publishing Group for libraries and other users registered with the Copyright Clearance Center (CCC) Transaction Reporting Service, provided that the base fee of \$25.00 per copy is paid directly to CCC, 222 Rosewood Drive, Danvers, MA 01923, USA. 0007–1188/02 \$25.00 + \$0.00.

Apart from any fair dealing for the purposes of research or private study, or criticism or review, as permitted under the Copyright, Designs and Patent Act 1988, this publication may be reproduced, stored or transmitted,

INDEX TO PROCEEDINGS SUPPLEMENT

University of Hertfordshire (Hatfield Campus) 11th–12th April, 2002

Author Index

- Aitken J *see* Liddle R, 49P
Aitken J *see* Liddle R, 50P
Akil H *see* Nicholson JR, 17P
Al-Damluji, S & Ganellin, CR Structural properties of Group B ligands for transport-P, 20P
AliAbadi FS *see* Lees P, 25P
Amantea D *see* Bowery N, 79P
Anavi-Goffer S *see* Coutts AA, 11P
Andersson H, Summers A, Ihenetu K & Whelan CJ Induction of apoptosis in the epithelial cell line HT29 by nicotine and tobacco smoke condensate, 39P
Andrews M, Waterworth T, Rickards K & Cunningham F Effect of phosphodiesterase inhibitors on equine platelet aggregation, 35P
Arifah AK *see* Lees P, 24P
Arkle MJM, Arkle S & Ebenezer IS Investigation of the mechanism of tolerance to the anorexigenic effects of 8-hydroxy-2-(di-*N*-propylamino)-tetralin (8-OH-DPAT) in food-deprived rats, 70P
Arkle S *see* Arkle MJM, 70P
Ashmeade T *see* Gartlon J, 66P
Aston JC & Elliott JM Paroxetine modulates the expression of the immediate early gene arc induced by MDMA in rat brain, 65P
Bailey SR, Berhane Y & Elliott J Effects of tryptamine on the equine isolated perfused digit preparation, 27P
Baird AW *see* Cochrane S, 44P
Baird AW *see* Forrest AS, 45P
Baird AW *see* Murphy JEJ, 64P
Baird AW *see* Quinn T, 46P
Baker JG, Hall IP & Hill SJ Antagonism of isoprenaline- and salbutamol-stimulated cyclic AMP accumulation by β_2 -antagonists in CHO-K1 cells expressing the human β_2 -adrenoceptor, 51P
Baker JG, Hall IP & Hill SJ Response-dependent agonist and inverse agonist properties of propranolol at the human β_2 -adrenoceptor expressed in CHO-K1 cells, 5P
Barreca ML *see* De Sarro G, 60P
Baydoun AR, Dawson J, Thakur S & Knowles RG Transport mechanisms for GW274150, a potent and selective inhibitor of inducible nitric oxide synthase, 33P
Baydoun AR *see* Cui Z, 2P
Baydoun AR *see* Gasseem F, 32P
Baydoun AR *see* Konstantinidis M, 1P
Baydoun AR *see* Thakur S, 3P
Bennett MR *see* Wiley KE, 28P
Berhane Y *see* Bailey SR, 27P
Beveridge TJR & Elliott JM Down-regulation of the 5-HT_{2A} receptor by mianserin in rat brain is associated with a change in expression of the immediate early gene Arc, 19P
Borman RA, Coleman RA & Clark KL Investigation of the excitatory effects of 5-HT on contractile responses of human colon smooth muscle, 43P
Bowery B *see* Bowery N, 79P
Bowery NG Mammalian presynaptic GABA_B receptors, 79P
Brahmadevara N, Shaw AM & MacDonald A Effects of endothelium and pre-constriction on β -adrenoceptor-mediated relaxation in rat isolated aorta, 30P
Bramhall J *see* Klee S, 10P
Brayden DJ *see* Cochrane S, 44P
Brayden DJ *see* Forrest AS, 45P
Brera B *see* de Ceballos ML, 22P
Briddon SJ, Cordeaux Y, Middleton RJ, Kellam B & Hill SJ Visualisation of adenosine-A₁ receptors using the novel fluorescent ligand, xanthine amine cogener-bodipy630/650, 6P
Broadley KJ *see* Clark JH, 38P
Broadley KJ *see* Nevin BJ, 37P
Brooks JW, Rice ASC, Thompson SWN & Malcangio M (*S*)-amphipip inhibits electrically evoked calcitonin gene-related peptide (CGRP) release from the rat dorsal horn: reversal by cannabinoid antagonist SR141716A, 16P
Brown MJ *see* Turner RR, 29P
Brownhill V *see* Liddle R, 50P
Brzeski H *see* Gasseem F, 32P
Brzeski H *see* Thakur S, 3P
Calvert G *see* Cumberbatch N, 48P
Cameron NE *see* Ross RA, 12P
Chapman V *see* Kelly S, 15P
Chari R, Iannazzo L & Majewski H The conventional isoforms of protein kinase C are targeted in the endogenous facilitation of nor-

- adrenaline release in the rat brain cortex, 54P
- Cheetham SC *see* Cumberbatch N, 48P
- Cheetham SC *see* Liddle R, 49P
- Cheetham SC *see* Liddle R, 50P
- Chimirri A *see* De Sarro G, 60P
- Clark JH, Martin TJ, Yates L, Kidd EJ, Nicholson RI & Broadley KJ Characterisation of transfected human adenosine A3 receptors, 38P
- Clark KL *see* Borman RA, 43P
- Clarke RW *see* Jenkins S, 69P
- Cochrane S, Quinn T, O'Donoghue DP, Baird AW & Brayden DJ The effect of myosin light chain kinase inhibition on pharmacologically induced changes in paracellular intestinal epithelial permeability, 44P
- Cockcroft V *see* Cumberbatch N, 48P
- Cockcroft V *see* Liddle R, 49P
- Coleman RA *see* Borman RA, 43P
- Collins GGS *see* Dewhurst DG, 73P
- Cordeaux Y *see* Briddon SJ, 6P
- Cotter MA *see* Ross RA, 12P
- Coutts A & Anavi-Goffer S Vanilloid receptor type 1-immunoreactivity and calcium binding proteins in the guinea-pig myenteric plexus, 11P
- Craib SJ, Thomas A, Ross RA & Pertwee RG Cannabidiol attenuates responses of the mouse isolated vas deferens to WIN55212-2 and noradrenalin, 53P
- Cromar S *see* Dewhurst DG, 73P
- Croucher MJ *see* Lee JJ, 58P
- Cui Z, Tuladhar R, Hart S, Marber M, Pearson J & Baydoun AR Inducible nitric oxide synthase alone does not enhance transport of L-arginine in HEK293 cells, 2P
- Cui Z *see* Thakur S, 3P
- Cumberbatch N, Calver G, Thompson KSJ, Cheetham SC, Watts JP & Cockcroft V Identification of the critical residues in melanin concentrating hormone (MCH) involved in human MCH₁ (SLC-1) receptor activation, 48P
- Cunningham F *see* Andrews M, 35P
- Cunningham FM *see* Greenaway EC, 34P
- Cunningham JR *see* Lever IJ, 56P
- Dass N *see* Murray C, 18P
- Davenport AP *see* Wiley KE, 28P
- Dawson J *see* Baydoun AR, 33P
- Dawson L *see* Messenger MJ, 59P
- Dayan L & Finberg JPM L-DOPA increases intraneuronal release of noradrenaline in rat frontal cortex, 21P
- de Ceballos ML, Brera B & Fernández-Tomé MP β -Amyloid₂₅₋₃₅ inhibits Glutamate uptake in cultured neurons and astrocytes: Modulation of uptake as a survival mechanism, 22P
- De Sarro G, Ferreri G, Russo E, Gitto R, Barreca ML & Chimirri A Anticonvulsant activity of tetrahydroisoquinoline derivatives as potential new ampa receptor antagonists, 60P
- Dewhurst DG, Collins GGS & Cromar S A computer simulation of the sciatic nerve-tibialis anterior muscle preparation of the cat *in vivo* to teach neuromuscular pharmacology to undergraduate students, 73P
- Dickenson A Recent advances in mechanisms of pain, 84P
- Doyle KM *see* Pantasri P, 40P
- Drummond RM *see* Seatter MJ, 4P
- Duncan M, Kendall DA & Ralevic V The endocannabinoid noladin ether attenuates sensory neurotransmission in the rat isolated mesenteric arterial bed, 13P
- Duty S *see* Johnston T, 23P
- Duty S *see* Messenger MJ, 59P
- Duxon M *see* Gartlon J, 66P
- Ebenezer IS Pretreatment with the CCK1 receptor antagonist attenuates the suppressant effect of the 5-HT_{1A} receptor agonist gepirone on food intake in hungry rats, 71P
- Ebenezer IS *see* Arkle MJM, 70P
- Ebenezer IS *see* Patel JD, 41P
- Ebenezer IS *see* Patel SM, 72P
- Ellington HC *see* Ross RA, 12P
- Elliott J *see* Bailey SR, 27P
- Elliott J *see* Katz LM, 8P
- Elliott JM *see* Aston JC, 65P
- Elliott JM *see* Beveridge TJR, 19P
- Emmanuel A *see* Murray C, 18P
- Fernández-Tomé MP *see* de Ceballos ML, 22P
- Fernyhough P *see* Tomlinson DR, 74P
- Ferreri G *see* De Sarro G, 60P
- Féléto M *see* Yang D, 7P
- Finberg JPM *see* Dayan L, 21P
- Forrest AS, Quinn T, Keenan AK, Usher C, Parsons ME, Baird AW & Brayden DJ Megacolon in the streptozotocin treated diabetic rat, 45P
- Forrest AS *see* Talubmook C, 42P
- Foxwell N *see* Gasse F, 32P
- Ganellin CR *see* Al-Damluji S, 20P
- Gartlon J, Ashmeade T, Duxon M, Jones DNC & Hagan JJ C-fos induction following central administration of urotensin-II, 66P
- Gasse F, Brzeski H, Foxwell N & Baydoun AR Characteristics of L-arginine transport and nitric oxide synthesis in the p53 mutated CAPAN-1 human pancreatic tumour cell line, 32P
- Gitto R *see* De Sarro G, 60P
- Goode NT *see* Greenaway EC, 34P
- Greenaway EC, Goode NT & Cunningham FM Role of protein kinase C in equine eosinophil superoxide production and adherence, 34P
- Greenwood IA, Ohya S & Horowitz B Characterization of murine ERG1a channels expressed in HEK cells, 26P
- Guiry PJ *see* Murphy JEJ, 64P
- Hagan JJ *see* Gartlon J, 66P
- Hall IP *see* Baker JG, 5P
- Hall IP *see* Baker JG, 51P
- Han J *see* Konstantinidis M, 1P
- Hart S *see* Cui Z, 2P
- Hart S *see* Konstantinidis M, 1P
- Hill RG Pain and its treatment, 75P
- Hill SJ *see* Baker JG, 5P
- Hill SJ *see* Baker JG, 51P
- Hill SJ *see* Briddon SJ, 6P
- Hoffman R *see* Pantasri P, 40P
- Hoffman R *see* Young JJ, 36P
- Horowitz B *see* Greenwood IA, 26P
- Iannazzo L *see* Chari R, 54P
- Ihenetu K, Salmon DM, Molleman A, Parsons M & Whelan CJ Cannabinoids decrease intracellular Ca²⁺ and inhibit ligand-induced rises in [Ca²⁺]_i in an epithelial cell line (HT29), 14P
- Ihenetu K *see* Andersson H, 39P
- Jane DE *see* More JCA, 67P
- Jenkins S, Tucker L & Clarke RW Evidence that excitatory spinal actions of a triptan are mediated through 5-HT₇ receptors, 69P
- Jenner P Mechanisms of neurodegeneration in CNS disorders such as Parkinson's disease, 77P
- Jenner P *see* Tel BC, 68P
- Johnston T & Duty S Baclofen alleviates akinesia following intranigral and intraventricular injection in the reserpine-treated rat but fails to inhibit

- glutamate release from rat nigral slices, 23P
- Jones DNC *see* Gartlon J, 66P
- Kang KB, van der Zyppe A, Rajanayagam MAS & Majewski H Effects of aging on cyclooxygenase expression and the α_1 -adrenoceptor signaling pathway in rat aortae, 31P
- Kanke T *see* Scatter MJ, 4P
- Katz LM, Marr CM & Elliott J Characterisation of the relaxant responses of equine digital blood vessels to substance P, 8P
- Keenan AK *see* Forrest AS, 45P
- Keenan AK *see* Murphy JEJ, 64P
- Kellam B *see* Briddon SJ, 6P
- Kelly PAT *see* Quate L, 63P
- Kelly S & Chapman V The effect of a selective cannabinoid CB1 receptor agonist on mechanical punctate evoked responses of spinal neurons in anaesthetised rats, 15P
- Kendall DA *see* Duncan M, 13P
- Kendall DA *see* Overbury AL, 52P
- Khundakar AA, Mazumdar A & Zetterström TSC Gene expression for brain derived neurotrophic factor in rat hippocampus is reduced by baclofen, tranlycypromine and paroxetine but not flunitrazepam, 57P
- Kidd EJ *see* Clark JH, 38P
- Klee S, Bramhall J, Vecchione A, Sykes A, Parsons ME & Whelan CJ Characterisation of the nicotine receptor mediating inhibition of TNF α release from THP-1 cells *in vitro*, 10P
- Knowles RG *see* Baydoun AR, 33P
- Konstantinidis M, Hart S, Han J, Marber M, Pearson J & Baydoun AR Regulation of inducible nitric oxide synthase and cationic amino acid transport by p38a and p38b MAP kinases in rat cultured aortic smooth muscle cells, 1P
- Kramer K *see* Pantasri P, 40P
- Lähdesmäki J *see* MacDonald E, 62P
- Landoni MF *see* Lees P, 24P
- Langer SZ An overview of presynaptic receptors, 78P
- Lee JJ & Croucher MJ Differential roles of Group I and Group II mGlu receptors in the regulation of 5-HT release in the rat frontal cortex *in vivo*, 58P
- Lees P, Arifah AK & Landoni MF Pharmacodynamics, chiral pharmacokinetics and PK-PD modelling of ketoprofen in the goat, 24P
- Lees P & Shojaee AliAbadi F Pharmacokinetics, pharmacodynamics and PK-PD integration of danofloxacin in sheep biological fluids, 25P
- Lees P Large animal models in studies of the pharmacology of anti-inflammatory drugs, 82P
- Levens N *see* Yang D, 7P
- Lever IJ, Cunningham JR, Pezet S & Malcangio M BDNF facilitates potassium stimulated GABA release from the isolated rat dorsal horn, 56P
- Liddle R, Aitken J, Oldfield K, Brownhill V & Cheetham S Characterisation of [3 H]-Phe 13 , Tyr 19 -MCH binding to human MCH $_1$ (SLC-1) receptors, 50P
- Liddle R, Aitken J, Oldfield K, Watts JP, Cockcroft V & Cheetham SC Residues in melanin concentrating hormone (MCH) involved in high affinity binding to MCH $_1$ (SLC-1) receptors, 49P
- Lightbown ID, Miner WD & Gale JD The anti-emetic activity of S(-)-eticlopride against morphine- and ipecacuanha-induced emesis in the conscious ferret, 61P
- Lord PG *see* Pantasri P, 40P
- Lummis SCR *see* Valentine SM, 47P
- McBean DE *see* Quate L, 63P
- McBean GJ *see* Murphy JEJ, 64P
- McCormack P *see* Murphy JEJ, 64P
- MacDonald A *see* Brahmadevara N, 30P
- MacDonald E, Lähdesmäki J, Sallinen J & Scheinin M The α_{2A} -adrenoceptor is activated after amphetamine administration and protects hippocampal noradrenergic nerves in mice from transmitter depletion, 62P
- Macfarlane SR *see* Scatter MJ, 4P
- McKellar Q Antimicrobial resistance: designing dosage schedules on basic pharmacological principles, 83P
- McKnight AT Presynaptic opioid receptors, 80P
- Majewski H *see* Chari R, 54P
- Majewski H *see* Kang KB, 31P
- Malcangio M *see* Brooks JW, 16P
- Malcangio M *see* Lever IJ, 56P
- Marber M *see* Cui Z, 2P
- Marber M *see* Konstantinidis M, 1P
- Marr CM *see* Katz LM, 8P
- Marsden CA *see* Overbury AL, 52P
- Martin TJ *see* Clark JH, 38P
- Mazumdar A *see* Khundakar AA, 57P
- Messenger MJ, Dawson L & Duty S Changes in Group I, II and III metabotropic glutamate (mGlu) receptor gene expression in the basal ganglia and thalamus of rats with a nigrostriatal tract lesion, 59P
- Meza-Toledo S *see* Bowery N, 79P
- Middleton RJ *see* Briddon SJ, 6P
- Milla P The enteric nervous system and its contribution to gastrointestinal disorders, 76P
- Molleman A *see* Ihenetu K, 14P
- Molloy M *see* Quinn T, 46P
- More JCA, Troop HM & Jane DE N^3 -tetrazolylalkylwillardiine analogues are AMPA and kainate receptor antagonists, 67P
- Murphy JEJ, McBean GJ, Guiry PJ, McCormack P, Baird AW & Keenan AK *In vitro* effects of (\pm)-4-methylthioamphetamine, (\pm)-4-methylthioamphetamine and (\pm)-MDMA on vascular responses to noradrenaline and phenylephrine, 64P
- Murray C, Dass N, Emmanuel A & Sanger GJ Facilitation by ghrelin and metoclopramide of nerve-mediated excitatory responses in mouse gastric fundus circular muscle, 18P
- Nevin BJ & Broadley KJ Effects of selective inducible nitric oxide synthase (iNOS) inhibition on allergen-induced airway responses in conscious guinea-pigs, 37P
- Nicholson JR, Akil H & Watson SJ The involvement of nociceptin/orphanin FQ in the physiological mediation of feeding behaviour in rats, 17P
- Nicholson RI *see* Clark JH, 38P
- Nolan A Use of large animal models in pain research, 85P
- O'Donoghue DP *see* Cochrane S, 44P
- Ohya S *see* Greenwood IA, 26P
- Oldfield K *see* Liddle R, 49P
- Oldfield K *see* Liddle R, 50P
- Olverman HJ *see* Quate L, 63P
- Overbury AL, Kendall DA & Marsden CA The effect of 5-HT depletion on central cannabinoid receptor function, 52P
- Pantasri P, Rapley R, Hoffman R, Walker JM, Lord PG, Skehel MJ, Kramer K & Doyle KM Protein expression in rat liver: response to

- short term treatment with phenobarbital using two-dimensional gel electrophoresis, 40P
- Parsons M *see* Ihenetu K, 14P
- Parsons M *see* Young JJ, 36P
- Parsons ME *see* Forrest AS, 45P
- Parsons ME *see* Klee S, 10P
- Parsons ME *see* Nicholson JR, 17P
- Parsons ME *see* Summers AE, 9P
- Parsons ME *see* Talubmook C, 42P
- Patel, JD & Ebenezer IS Previous exposure to cholecystokinin sensitises the guinea pig isolated ileum to the contractile effects of acetylcholine, 41P
- Patel SM & Ebenezer IS Effects of chronic administration of the GABA_B agonist baclofen on food intake in rats, 72P
- Pearson J *see* Cui Z, 2P
- Pearson J *see* Konstantinidis M, 1P
- Pertwee R Presynaptic cannabinoid receptors, 81P
- Pertwee RG *see* Craib SJ, 53P
- Pezet S *see* Lever IJ, 56P
- Plevin R *see* Seatter MJ, 4P
- Princivalle A *see* Bowery N, 79P
- Pullar I *see* Rousseau S, 55P
- Purves T *see* Tomlinson DR, 74P
- Quate L, McBean DE, Ritchie IM, Olverman HJ & Kelly PAT Acute methylenedioxymethamphetamine administration: effects on local cerebral blood flow and glucose utilisation in the rat, 63P
- Quinn T, Molloy M, Smith A & Baird AW Capacitative calcium entry in guinea-pig gallbladder smooth muscle, 46P
- Quinn T *see* Cochrane S, 44P
- Quinn T *see* Forrest AS, 45P
- Rajanayagam MAS *see* Kang KB, 31P
- Ralevic V *see* Duncan M, 13P
- Rapley R *see* Pantasri P, 40P
- Rice ASC *see* Brooks JW, 16P
- Rickards K *see* Andrews M, 35P
- Ritchie IM *see* Quate L, 63P
- Rose S *see* Tel BC, 68P
- Ross RA, Ellington HC, Cotter MA & Cameron NE The effect of cannabinoids on capsaicin-evoked calcitonin gene-related peptide (CGRP) release from the isolated hindpaw skin of diabetic and non-diabetic rats, 12P
- Ross RA *see* Craib SJ, 53P
- Rousseau S, Wonnacott S & Pullar I Activation of presynaptic nicotinic acetylcholine receptors modulates the depolarisation dependent release of [³H]-D-aspartate from rat frontal cortex synaptosomes, 55P
- Russo E *see* De Sarro G, 60P
- Sallinen J *see* MacDonald E, 62P
- Salmon DM *see* Ihenetu K, 14P
- Sanger GJ *see* Murray C, 18P
- Scheinin M *see* MacDonald E, 62P
- Seatter MJ, Drummond RM, Macfarlane SR, Kanke T & Plevin R The role of the C-terminus in protease-activated receptor-2-mediated intracellular Ca²⁺ signalling, PYK-2 activation and mitogen-activated protein kinase activity, 4P
- Shaw AM *see* Brahmadevara N, 30P
- Skehel MJ *see* Pantasri P, 40P
- Smith A *see* Quinn T, 46P
- Smith E *see* Young JJ, 36P
- Stoneman VEA *see* Wiley KE, 28P
- Summers A, Parsons ME & Whelan CJ Characterisation of nicotine receptors in the human lymphocytic cell line Jurkat, 9P
- Summers AE *see* Andersson H, 39P
- Sykes A *see* Klee S, 10P
- Talubmook C, Forrest AS & Parsons ME Alterations in basal and evoked contractile responses of intestinal tissue from streptozotocin-induced diabetic rats, 42P
- Tel BC, Rose S & Jenner P Ropinirole, bromocriptine and L-DOPA have a differential effect on striatal dopamine D2 and D3 but not D1 receptor mRNA expression in MPTP-treated marmosets, 68P
- Thakur S, Cui Z, Brzeski H & Baydoun AR Requirement of NFκB for the induction of L-arginine transport in rat cultured aortic smooth muscle cells, 3P
- Thakur S *see* Baydoun AR, 33P
- Thomas A *see* Craib SJ, 53P
- Thompson KSJ *see* Cumberbatch N, 48P
- Thompson SWN *see* Brooks JW, 16P
- Tomlinson DR, Purves T & Fernyhough P Diabetic neuropathies, 74P
- Troop HM *see* More JCA, 67P
- Tucker L *see* Jenkins S, 69P
- Tuladhara R *see* Cui Z, 2P
- Turner RR & Brown MJ Identification of a novel variant in exon 19 of the endothelial nitric oxide synthase gene, 29P
- Usher C *see* Forrest AS, 45P
- Valentine SM & Lummis SCR The role of non-conserved proline residues in the extracellular domain of the mouse 5-HT_{3A} receptor, 47P
- van der Zyppe A *see* Kang KB, 31P
- Vanhoutte PM *see* Yang D, 7P
- Vecchione A *see* Klee S, 10P
- Walker JM *see* Pantasri P, 40P
- Waterworth T *see* Andrews M, 35P
- Watson SJ *see* Nicholson JR, 17P
- Watts JP *see* Cumberbatch N, 48P
- Watts JP *see* Liddle R, 49P
- Whelan CJ *see* Andersson H, 39P
- Whelan CJ *see* Ihenetu K, 14P
- Whelan CJ *see* Klee S, 10P
- Whelan CJ *see* Summers AE, 9P
- Wiley KE, Stoneman VEA, Bennett MR & Davenport AP Increased vasoconstriction to endothelin-1 in aorta from apolipoprotein E deficient mice devoid of atherosclerotic lesions, 28P
- Wonnacott S *see* Rousseau S, 55P
- Yang D, Félétou M, Levens N, Zhang JN & Vanhoutte PM A diffusible substance mediates endothelium-dependent contractions in the aorta of spontaneously hypertensive rats, 7P
- Yates L *see* Clark JH, 38P
- Young JJ, Smith E & Hoffman R Detection of multiple forms of vascular endothelial growth factor (VEGF) and endostatin in leg ulcer fluid, 36P
- Zetterström TSC *see* Khundakar AA, 57P
- Zhang JN *see* Yang D, 7P

Keyword Index

- Acetylcholine 41P
Acetylcholine receptors 55P
Adenosine 6P
Adenosine A₃ receptors 38P
 α -Adrenoceptor antagonists 65P
 α_{2A} -Adrenoceptors 63P
 β -Adrenoceptors 5P, 30P, 51P
Ageing 31P
Aggregation 35P
Aminoguanidine 37P
AMPA antagonists 60P
Amphetamines 63P
 β -Amyloid 22P
Analgesics 84P
Angiogenesis 36P
Antagonists 51P, 67P
Antibiotic resistance 83P
Anticonvulsants 60P
Antidepressants 57P
Antiemetics 61P
Aorta 30P, 31P
Aorta, murine, 28P
Apolipoprotein E deficient mice 28P
Apoptosis 39P
[³H]-D-Aspartate release 55P
Asthma 37P
Atipamezole 63P
- B-50 54P
Baclofen 23P, 72P
BDNF mRNA 57P
Brain 19P
- Caco-2 44P
Calcitonin gene-related peptide 12P, 16P
Calcium 4P, 14P
cAMP 38P, 51P
cAMP accumulation 48P
Cannabidiol 53P, 81P
Cannabinoids 12P, 13P, 14P, 16P, 52P, 53P
Cannabinoid receptors 81P
Cannabinoid CB₁ receptors 15P, 52P
Capacitative calcium entry 46P
Carrageenan 15P
Cationic amino acid transport 1P, 2P, 3P, 32P, 33P
CB₁ receptors 15P, 52P
Cell death 77P
Cerebral cortex 58P
Cerebrovascular control 64P
c-fos 66P
Cholecystokinins 41P, 71P
Colon 43P
Computer simulations 73P
Contracting factor 7P
Contractions 46P
Cyclic AMP 38P, 51P
Cyclic AMP accumulation 48P
Cyclo-oxygenase 31P
Cytokines 10P
- Danofloxacin 25P
DBA/2 mice 60P
Diabetes 12P, 45P, 74P
Digital blood vessels 8P
L-DOPA 21P
Dopamine antagonists 62P
Dopamine receptors 68P
Down-regulation 19P
- Ecstasy 64P
Emesis 61P, 62P
Endocannabinoids 81P
Endostatin 36P
Endothelial nitric oxide synthase 29P
Endothelin-1 28P
Endothelium 7P, 14P, 30P
Enteric nervous system 18P, 76P
Equine digital blood vessels 8P
Equine eosinophils 34P
Equine laminitis 27P
Ether-a-go-go related genes 26P
(S)-Eticlopid 61P, 62P
Excitotoxicity 22P
- 24-Hour feeding 72P
Feeding 70P
Feeding behaviour 17P
Food intake 71P
Fundus 18P
- GABA 57P
GABA_A receptors 23P
GABA_B 72P
GABA_B receptors 79P
GABAergic terminals 79P
Gall bladder 46P
Gene transfection 2P
Gepirone 71P
Ghrelin 18P
GluR 67P
Glutamate uptake 22P
GPR14 66P
Gut function 76P
GW274150 33P
- 24-Hour feeding 72P
5-HT 19P, 43P, 47P, 52P, 64P, 69P
5-HT release 58P
Hypertension 7P
Hypothalamus 20P
- Ileum 41P
Imaging 6P
Immunohistochemistry 11P
In situ hybridisation 59P, 68P
Inducible nitric oxide synthase 1P, 2P, 3P, 33P
Inflammation 9P, 10P
Intestine 42P
Inverse agonists 5P
Ion transport 45P
Ischaemia 27P
- Ketoprofen 24P
- Large animal models 85P
Large animal species 82P
Ligand-gated ion channels 47P
Liver tumorigenesis 40P
Lymphocytes 9P
- MAP kinase 4P, 74P
MCH₁ receptors 48P

MCH₁ receptors, human 49P, 50P
 MDMA analogues 65P
 Megacolon 45P
 Melanin concentrating hormones 48P, 49P, 50P
 Mesenteric bed, rat 13P
 mGluR 58P, 59P
 Microdialysis 21P
 Migraine 69P
 Myenteric plexus 11P
 Myosin light chain kinase 44P

Neuromuscular pharmacology 73P
 Neuropathies 74P, 76P
 Nicotine 9P, 10P, 39P, 55P
 Nitric oxide 29P, 32P, 37P
 NMDA 84P
 Nociceptin 17P
 Nociception 69P, 80P
 Non-steroidal anti-inflammatory drugs 82P
 Noradrenaline 21P, 78P
 Noradrenaline release 54P
 Nuclear factor κ B 3P

8-OH-DPAT 70P
 Opioid receptors 80P
 ORL₁ receptors 80P
 Orphanin FQ 17P
 Oxidative stress 77P

p38 MAP kinase 1P
 p53 32P
 Pain 56P, 75P, 84P
 Pain research 85P
 Parkinson's disease 23P, 59P, 68P, 77P
 Pharmacodynamics 24P, 25P
 Pharmacokinetics 24P, 25P
 Phenobarbital 40P
 Phosphodiesterase 35P
 Platelets 35P
 Polymorphism 29P
 Potassium channels 26P
 Prazosin 20P
 Pre- and post-synaptic sites 79P
 Presynaptic nicotinic acetylcholine receptors 55P
 Presynaptic receptors, overview of 78P
 Proline 47P
 Propranolol 5P
 Protease-activated receptor-2 4P
 Protein kinase C 34P, C 54P
 Proteomics 40P

Radioligand binding 38P
 Radioligand receptors 49P, 50P
 Rat 42P

Sensory neurotransmission 13P
 Serotonin 19P, 43P, 47P, 52P, 64P, 69P
 Smooth muscle 43P

Spinal cord 15P, 16P, 56P
 Streptozotocin diabetes 42P
 Substance P 8P
 Superoxide 34P

Therapeutic advances 75P
 Tight junctions 44P
 Tobacco 39P
 Transgenic animals 75P
 Trophic factors 56P
 Tryptamine 27P

Undergraduate teaching 73P
 Uptake 20P
 Urotensin-II 66P

Vanilloids 11P
 Vascular endothelial growth factor 36P
 Vascular responses 65P
 Vascular smooth muscle cells 26P
 Veterinary pharmacology 82P, 83P, 85P

WAY 100635 70P
 Willardiine 67P
 WIN55212-2 53P

Xanthine amine cogeners 6P